ESC Premium Access

Targeting of PCSK9 with siRNA for LDL-C reduction in a high-risk population

Event: ESC CONGRESS 2019
Topic: Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)
Session type: Satellite Symposium
Sponsored by National Lipid Association
Date: 31 August 2019
Time: 15:30 - 16:45

Congress Session

5 presentations in this session

Clinical implications for patients at persistent ASCVD risk

Speaker: Doctor J. Saseen (Aurora, US)

Clinical trial updates

Speaker: Doctor C. Ballantyne (Houston, US)

The future of lipid management: new therapies for LDL-C lowering

Speaker: Doctor H. Bays (Louisville, US)

Post-activity quiz and discussion

Speaker: Doctor P. MORRIS (Charleston, US)

Questions and answers / Panel discussion


4 speakers from this session

Doctor Joseph Saseen

University of Colorado, Aurora (United States of America)
1 presentation
0 follower

Doctor Christie Ballantyne

Baylor College of Medicine, Houston (United States of America)
16 presentations
1 follower

Doctor Harold Bays

Louisville Metabolic and Atherosclerosis Research Center, Louisville (United States of America)
1 presentation
0 follower

Doctor Pamela MORRIS

Medical University of South Carolina, Charleston (United States of America)
2 presentations
0 follower

This platform is supported by

logo Novo Nordisk